Although the treatment of metastatic alveolar soft part sarcoma with antiangiogenic agents such as apatinib, bevacizumab, and sunitinib has not effectively prevented recurrence, antibodies targeting programmed cell death 1 and its ligand may improve survival rates in these patients. The gene discussed is PDCD1; the disease is alveolar soft part sarcoma.